Loading...
•
Sep 30, 2022
Optinose Q3 2022 Earnings Report
Reported financial results for Q3 2022 and provided operational updates.
Key Takeaways
Optinose reported Q3 2022 XHANCE net revenue of $20.1 million. The company anticipates submitting an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023. They expect full year 2022 XHANCE net revenue to be between $74 to $78 million and full year 2022 operating expenses to be between $127 to $131 million.
XHANCE net revenue for Q3 2022 was $20.1 million, a decrease of 8% compared to Q3 2021.
The company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023.
Full year 2022 XHANCE net revenue is expected to be between $74 to $78 million.
Full year 2022 operating expenses are expected to be between $127 to $131 million; full year 2023 operating expenses expected to decrease materially.
Forward Guidance
Optinose expects XHANCE net revenues for the full year of 2022 to be between $74 to $78 million and full year 2022 XHANCE average net revenue per prescription to be approximately $220. The company expects total GAAP operating expenses for 2022 to be in the range of $127 - $131 million. They also expect total GAAP operating expenses for full year 2023 to decrease materially compared to full year 2022 total GAAP operating expenses.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...